Skip to main content
main-content

Bone diseases

Feature content

01-03-2019 | Osteoarthritis | Highlight | Article

Early-onset osteoarthritis in association with familial angel-shaped phalango-epiphyseal dysplasia previously referred to as peripheral dysostosis

Editorial board member Oliver FitzGerald presents a family with two siblings having features consistent with angel-shaped phalango-epiphyseal dysplasia (ASPED), and a mother with a normal phenotype but with severe, early-onset multi-joint osteoarthritis.

18-02-2019 | Osteoporosis | Editorial | Article

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

31-05-2018 | Osteoporosis | View from the clinic | Article

Monitoring bone health with dual-energy X-ray absorptiometry in pediatric patients

Advisory board member and consultant endocrinologist Malachi McKenna summarizes the use of dual-energy X-ray absorptiometry in monitoring bone health and diagnosing low bone mineral mass in children.

31-05-2018 | Osteoporosis | View from the clinic | Article

Managing osteoporosis in pediatric patients

Editorial board member Sangeeta Sule discusses the causes of low bone mineral density and osteoporosis in pediatric patients with rheumatic diseases, and suggests strategies for risk prevention and treatment of this disease.

08-11-2017 | Osteoporosis | ACR/ARHP 2017 | Video

Expert commentary: Bisphosphonate drug holidays and fracture risk

Linda Russell gives an independent comment on a study showing that suspending bisphosphonate treatment for more than 2 years is associated with increased fracture risk.

Read the accompanying news story

Image Credits